• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Urgent Need for Consensus on Systemic Treatments for Atopic Dermatitis in Childbearing-Age Populations

Author(s):

Elizabeth Kiracofe, MD, FAAD,Jenny Murase, MD, FAAD

Experts on atopic dermatitis weigh the risks and rewards of systemic treatments for pregnant patients and provide clinical insights on monitoring for adverse effects associated with dupilumab.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Dispelling Skin Myths: A New Era of Preventative Care for Anti-Aging, Cleansing, and Sunscreen
December 20th 2024

Dispelling Skin Myths: A New Era of Preventative Care for Anti-Aging, Cleansing, and Sunscreen

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older
December 16th 2024

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis
December 16th 2024

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis

2024 Key Insights: Atopic Dermatitis
December 13th 2024

2024 Key Insights: Atopic Dermatitis

© 2024 MJH Life Sciences

All rights reserved.